SourceBio International PLC COVID-19 mobile testing labs management contract (6566P)
19 February 2021 - 6:00PM
UK Regulatory
TIDMSBI
RNS Number : 6566P
SourceBio International PLC
19 February 2021
SourceBio International plc
("SourceBio", the "Company" or the "Group")
COVID-19 mobile testing labs management contract
SourceBio to support roll-out of mobile units containing Oxford
Nanopore's LamPORE test
Mobile labs to meet demand for decentralised community testing
as part of the pandemic response
SourceBio International plc (AIM: SBI), the international
provider of integrated state-of-the-art laboratory services and
products , announces that it has entered into an agreement with
Mitie Security Limited ("Mitie") to manage the delivery of
community based COVID-19 testing services through mobile testing
units.
SourceBio will manage the delivery of the mobile COVID-19
testing laboratory service currently being deployed in a Department
of Health and Social Care ("DHSC") pilot scheme . SourceBio will
oversee all laboratory operations and processes and will have
responsibility for all clinical governance, quality assurance,
staff training, sample processing and information management.
Currently four mobile testing laboratories using Oxford
Nanopore's LamPORE tests for COVID-19 have been deployed in the
pilot which has been launched to support the Governments
community-based testing efforts and ensure that COVID-19 testing is
available for surge or increased infectious status within a
specified region.
SourceBio will manage the mobile testing service on behalf of
Mitie for the remainder of the pilot and is working towards
continued involvement in a potential UK-wide programme.
Larger mobile testing units can process in excess of 1,500
samples a day, with 1,000 tests a day targeted for smaller
vehicles. Patient swab samples are processed onboard with results
provided within 24 hours. Oxford Nanopore's LamPORE test has been
shown to be highly accurate for the detection of SARS-CoV-2. A
study carried out by teams across the UK on over 23,000 samples
have demonstrated gold-standard accuracy of the LamPORE test,
showing >99.5% sensitivity and specificity, making LamPORE
highly effect for testing symptomatic and asymptomatic
individuals.
SourceBio has worked closely with the DHSC providing COVID-19
antigen RT-PCR testing services using the Company's laboratory
facility. SourceBio has processed approaching 1,000,000 COVID-19
antigen RT-PCR tests for the DHSC and the NHS, Private Hospital
Groups and Commercial customers since first offering its service in
May 2020.
Jay LeCoque, Executive Chairman, commented: "We are very proud
to support the UK's national testing effort to bring gold standard
testing to the local communities as part of the effort to get the
nation back to work. The need for localised testing and monitoring
of infections is critical as the vaccine program accelerates. This
project also highlights our continued work with the DHSC on
multiple fronts as they work to manage the pandemic as it
evolves."
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Euan Brown
William Hall
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748
651 727
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products clients in the
healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA; and
-- Infectious Disease Testing - since May 2020, the Group has
provided COVID-19 Antigen RT-PCR testing services. These services
passed all of the auditing requirements of the NHS and the
Department of Health and Social Care (DHSC) in April 2020. It is
intended that this offering will potentially provide a broad range
of infectious disease testing across the NHS, private healthcare
and commercial sectors in the future.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market
of the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTDBGDDBSBDGBI
(END) Dow Jones Newswires
February 19, 2021 02:00 ET (07:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
